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Derivados 1,4-di-N-óxido Quinoxalinas: O Interesse no Tratamento da Doença 
de Chagas 
Resumo: Mais de 100 milhões de pessoas estão em risco de contrair a doença de Chagas. 
Estima-se que em 2008, mais de 10.000 pessoas morreram devido a esta patologia. Apesar de 
a doença ter sido descoberta há mais de 100 anos, ainda é preciso encontrar tratamento 
seguro e eficaz. Portanto, novos fármacos eficazes contra a doença de Chagas necessitam 
urgentemente serem descobertos. Derivados de quinoxalina apresentam interessantes 
propriedades biológicas (anti-infecciosa, citotóxica, anti-candida, anti-protozoário) e a 
avaliação de suas propriedades farmacológicas ainda está em andamento. Com respeito a isso, 
nós estamos há mais de uma década em busca de agentes anti-chagásicos. Nesta revisão 
mostramos nosso trabalho em andamento para identificação de novos agentes anti- T. cruzi 
com o padrão estrutural quinoxalina-di-N-óxido e apresentamos a relação estrutura-atividade 
observada entre as diferentes substituições nas posições C-2, C-3, C-6 e C-7 do anel da 
quinoxalina. 
Palavras-chave: Doença de Chagas; Trypanosoma cruzi; 1,4-di-N-óxido Quinoxalinas. 
Abstracts 
More than 100 million people are at risk of contracting Chagas disease. It is estimated that in 
2008, Chagas disease was responsible for the death of more than 10,000 people. Despite the 
fact that there are more than 100 years since the disease was discovered, safe and effective 
treatments still have to be found. Therefore, new drugs active against Chagas disease are 
urgently required. Quinoxaline derivatives show very interesting biological properties (anti-
infective, cytotoxic, anticandida, antiprotozoal) and evaluation of their medicinal chemistry is 
still in progress. In this regard, we have spent more than a decade in the search for anti-
Chagasic agents. In this review, we summarize our on-going work to identify new anti-T. cruzi 
agents with the quinoxaline-di-N-oxide scaffold. We present the structure-activity relationship 
observed among the different substitutions in C-2, C-3, C-6 and C-7 position of the quinoxaline 
ring. 
Keywords: Chagas disease; Trypanosoma cruzi; Quinoxaline 1,4-di-N-oxide. 
* Neglected Diseases Section. Drug R&D Unit, CIFA, University of Navarra. C/ Irunlarrea 1, 31008 
Pamplona, Spain. 
 sperez@unav.es  
Volume 5, Número 6 
 
Revista Virtual de Química 
ISSN 1984-6835 
Novembro-Dezembro 2013 
 
1102 Rev. Virtual Quim. |Vol 5|  |No. 6|  |1101-1119| 
 
Quinoxaline 1,4-di-N-oxide Derivatives: Interest in the 
Treatment of Chagas Disease 
Elsa Moreno-Viguri,a Silvia Pérez-Silanesb,* 
a Pharmacotherapy Lab., Instituto de Salud Tropical Universidad de Navarra. Avda. Pío XII, 55, 
31008 Pamplona, Spain. 
 b Neglected Diseases Section. Drug R & D Unit, CIFA, University of Navarra. C/ Irunlarrea 1, 
31008 Pamplona, Spain. 
* sperez@unav.es   
 
Recebido em 15 de abril de 2013. Aceito para publicação em 13 de agosto de 2013 
 
1. Introduction 
2. Background 
3. Ten years of research 
4. Complementary assays 
5. Conclusions 
 
1. Introduction 
 
Chagas disease, also known as American 
trypanosomiasis, is a potentially life-
threatening illness caused by the protozoan 
parasite, Trypanosoma cruzi (T. cruzi). It is 
mainly found in Latin America, where it is 
mostly transmitted to humans through the 
feces of triatomine bugs. According to the 
World Health Organization, 8 million people 
are infected with T. cruzi worldwide, with the 
majority of the cases occurring in Latin 
America, where Chagas disease is endemic.1,2 
However, it has now spread to other 
continents due to migration patterns; in the 
past few decades, the cases of Chagas 
disease has increased in the United States of 
America and Canada as well as in many 
European and some Western Pacific 
countries. More than 100 million people are 
at risk of the disease. It is estimated that in 
2008, Chagas disease killed more than 10,000 
people.  
Despite the fact that it has been more 
than 100 years since the disease was 
discovered, safe and effective treatments 
have yet to be found. Currently, vector 
control is the most useful method for 
preventing Chagas disease in Latin America. 
Chagas disease is curable if treatment is 
initiated soon after infection.3-6 Up to 30% of 
chronically infected people develops cardiac 
alterations and up to 10% develop digestive, 
neurological or mixed alterations for which 
specific treatment may be necessary. Only 
two drugs have been commercialized, 
Nifurtimox (Nfx) and Benznidazole (Bzn), and 
both drugs have some of limitations, such as 
low activity in the chronic phase of the 
disease, emergence of resistance, and 
toxicity (Figure 1). Therefore, there is an 
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urgent need to develop new, safe and 
effective therapeutic alternatives that are 
also cost-effective. 
The quinoxaline scaffold is present in 
several compounds that show very 
interesting biological properties and there is 
active interest in their research concerning 
medicinal chemistry. More importantly, its 
oxidized form, 1,4-di-N-oxide (QDO) 
derivatives, greatly increases the biological 
properties of the structure.7 In fact, the QDO 
are known as being anti-infective agents and 
they are cytotoxic against hypoxic cells 
present in solid tumours, with anticandida, 
antiprotozoal and mutagenic properties, 
depending on specific chemical features.8-16 
 
 
Figure 1. Nifurtimox and Benznidazole structures 
 
Furthermore, it is well-known that some 
QDO are species that suffer a bioreductive 
process under hypoxic conditions, producing 
hydroxyl radical and quinoxaline. Similar to 
the nitro pharmacophore of 
antitrypanosomal drugs, the N-oxide moiety 
of the quinoxaline could produce parasitic 
damage through the production of radical 
species affecting the redox metabolism.15 As 
previously described,17 the absence of the N-
oxide moiety produces a decrease in the anti-
epimastigote activity, thereby confirming 
that this group plays a key role in the 
mechanism of QDO antitrypanosomal 
activity.18 
Based on this idea, and in the search for 
more selective and less toxic anti-Chagas 
drugs, our synthesis group, led by professor 
Monge, has synthesized different series of 
quinoxaline-1,4-di-N-oxide derivatives, with a 
great variety of substituents in positions 2, 3, 
6 and 7 (Figure 2). Here is a summary of more 
than one decade of work carried out in close 
collaboration with the University of Uruguay, 
whose research personnel have conducted 
the biological activity assays. 
 
 
Figure 2. General structure of quinoxaline 1,4-di-N-oxide (QDO) 
 
2. Background 
 
Trypanothione reductase (TR) is the most 
thoroughly studied enzyme of the 
trypanothione redox metabolism. Despite 
40% identity in their primary sequences, TR 
and human glutathione reductase are 
exclusive towards their respective substrate 
trypanothione and glutathione. So, TR is a 
key enzyme of the parasite anti-oxidant 
defense system; however, it does not occur 
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in the mammalian host. Therefore, TR 
emerged as one of the most promising 
targets in the development of new anti-
trypanosomatid agents.19-22 Mepacrine, 4 (in 
the US, known as quinacrine), was the first 
tricyclic compound identified as a 
competitive inhibitor of T. cruzi TR, but not of 
human glutathione reductase (GR). Molecular 
modeling of the active center of TR led to the 
design of phenothiazines and other tricyclic 
compounds as potent inhibitors of TR (Figure 
3).23-25 
 
 
Figure 3. Inhibitors of T. Cruzi Trypanothione reductase 
 
Some quinoxaline derivatives developed 
by Monge and coworkers resembled the 
skeleton of these inhibitors.23-27 The activity 
of some of the most powerful TR inhibitors is 
not only due to the capability for inhibition, 
but also due to their redox activity.28,29 In this 
sense, when the QDO scaffold is considered, 
the resulting compounds are capable of 
acting as substrate of reductive enzymes, 
generating reactive oxygen species. These 
two facts and the ability of QDO to act as 
anti-infective agents towards a great number 
of microorganisms encouraged us to evaluate 
some selected quinoxalines for their anti-
trypanosomatid activity. 
The first contribution regarding 
quinoxaline derivatives with antichagas 
activity goes back to the year 2002. Thirty-
three quinoxaline derivatives were selected 
taking into account their volume, polarity, 
lipophilicity and electrochemical behavior 
(Figure 4). The selected compounds were 
evaluated for their in vitro activity against T. 
cruzi Tulahuen strain. Moreover, the IC50 in 
Tulahuen and Brener strains were 
determined for six derivatives showing a PGI 
(Percentage of Growth Inhibition) greater 
than 80%.23,27 
 
 
 
Figure 4. General structures of some selected QDO derivatives 
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In this first approach, five compounds (11-
15) showed very promising results and 
emerged as an excellent starting point for 
future structural modifications of the QDO 
scaffold in an effort to develop new anti-
trypanosomatid agents (Figure 5). 
 
 
 
Figure 5. The most potent quinoxaline derivatives evaluated against T. cruzi in the first 
screening. IC50: epimastigote form of T. Cruzi growth 
 
3. Ten years of research 
 
These in vitro results indicated that QDO 
hold promise for the treatment of Chagas 
disease. Therefore, a study considering the 
quinoxaline scaffold for the search of new 
anti-trypanosomatid agents was developed. 
 
3.1. Vanadium complexes 
 
With the aim of improving the 
bioavailability of quinoxaline derivatives, 
some vanadyl complexes of 3-
aminoquinoxalin-2-carbonitrile 1,4-di-N-oxide 
were prepared.30 
Seven complexes were prepared (Figure 6, 
general structure 17) and their in vitro 
activity against the epimastigote form of T. 
Cruzi (Tulahuen 2) was studied. The results 
revealed that 3 of the complexes showed a 
PGI higher than 80% and all of them 
improved the activity compared with their 
corresponding free ligands. 
Moreover the lipophilicity of the new 
complexes was studied and some structure-
activity relationships were performed. The 
studies revealed that vanadium complexation 
improves the solubility in hydrophilic media 
of the quinoxaline scaffold. 
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Figure 6. General structure of quinoxaline free ligands and their corresponding vanadyl 
complexes 
 
3.2. N-acylhydrazones 
 
In collaboration with LASSBio research 
laboratory located in Rio de Janeiro, we have 
designed, synthesized, performed docking 
studies and evaluated the trypanocidal 
activity of novel quinoxaline-N-acylhydrazone 
derivatives.31 The idea of synthesizing this 
type of compounds originates from the 
publication of some N-acylhydrazone 
derivatives as bioactive compounds with anti-
trypanosome activity.32,33 We studied the 
ability of the new derivatives to inhibit the 
parasite growth at the doses of 25 M. Two 
out of the sixteen synthesized compounds 
(19, 20) presented IC50 values of the same 
order of magnitude as the standard drug Nfx 
(IC50=7.7µM). (Figure 7). The activity data and 
their low cytotoxicity revealed these 
compounds as promising lead compounds.  
In an attempt to theoretically explain the 
difference found in the trypanocidal activity 
of the new quinoxaline N-acylhydrazone 
derivatives, docking studies using the cruzain 
enzyme were performed. 
These studies showed that a reasonable 
correlation exists in the molecular design of 
the quinoxaline derivatives so that they have 
affinity for the cruzain enzyme. The 
prediction values in silico (AG bind values), 
that were obtained by docking studies, 
pointed out compounds 19 and 20 as the 
most promising inhibitors, assuming that the 
molecular mechanism of these compounds 
involves this cruzain target. These studies 
also suggest that low bioactivity may be due 
to a lack of adequate distances to the sulphur 
atom of the Cys25 of cruzain. 
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Figure 7. General structure of quinoxaline (E/Z)-N-acylhydrazones and the most active 
compounds 
 
3.3. 2-Amide-3-carbonitrilederivatives 
 
Another example of our research group in 
an attempt to obtain a new hybrid QDO 
derivative with potential anti-tubercular and 
anti-T. cruzi activity is described here.34 First 
of all, nitrofuryl moiety is present in Nfx 
(compound 1 in Figure 1) and in a large 
number of anti-T. cruzi agents acting via a 
nitro-reduction process.18 In 2004, 
Tangallapally and coworkers35 published that 
nitrofuryl derivatives have the requirements 
for optimum inhibition of UDP-
galactosemutase (compound 24 in Figure 8), 
responsible for the biosynthesis of 
galactofuranose, an essential component of 
the mycobacterial cell wall. In addition, we 
have QDO with good in vitro selectivity 
against M. tuberculosis (compounds 21 and 
22 in Figure 8) and against T. cruzi 
(compound 23 in Figure 8). Therefore, we 
decided to design a new series of QDO amide 
derivatives with dual anti-tubercular and 
anti-chagas activity (Figure 8). 
Although the hybridization process, 
pharmacophore QDO plus pharmacophore 
nitrofuran, does not produce dual active 
compounds. The derivatives 26 and 27 
showed interesting antichagas activity. 
Moreover, it was observed that the activity 
increases for the compounds that have the 
most electron withdrawing groups. 
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Figure 8. Design of new heterocyclic-2-carboxylic acid (3-cyano-1,4-di-N-oxidequinoxalin-2-
yl)amide derivatives and the most active compounds 26 and 27, against T. cruzi Tulahuen 2 
strain. MIC: Minimum inhibitory concentration against M. tuberculosis H37Rv; PGI: Percentage 
of growth inhibition of epimastigote form of Tulahuen 2 strain at 25 M doses; IC50: 
concentration (in M) that inhibits 50% of epimastigote form of T. Cruzi growth 
 
3.4. 3-aryl- 2-carbonitrile derivatives 
 
In a continuing effort to identify new 
active compounds that can combat Chagas 
disease and other neglected diseases, our 
research group prepared 23 new 3-
arylquinoxaline-di-N-oxide derivatives.36 
Several structural modifications were 
introduced at the lead compounds 11, 12, 26 
and 27 (Figure 9) by applying the isosteric 
and homologous strategies (for instance 
elimination of the piperazinyl ring or by 
replacement of a methyl with a phenyl group) 
attempting to increase their lipophilic 
properties. We synthesized two series, 
maintaining the carbonitrile group linked to 
C-2 and with the aromatic group directly 
linked in C-3. Almost all of the compounds 
were active against the Tulahuen 2 strain, 
inhibiting growth > 50% at doses 25 M. The 
most active compounds 29-30 and 33-34 are 
showed in Figure 9. 
In view of the results achieved and in a 
further attempt to improve the biological 
profile of these QDO, we applied the QSAR 
models that we had developed in order to 
estimate the antitrypanosomal parameters of 
new possible antichagasic candidates. The 
proposed structures are presented in Figure 
10. 
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Figure 9. Design of 3-arylquinoxaline-2-carbonitrile di-N-oxide as anti-trypanosomal drugs 
from previous lead compounds with structural modifications and the most active compounds 
obtained 
 
 
Figure 10. Structure of the three best resulting anti-trypanosomal derivatives, as predicted by 
QSAR among the 49 newly proposed 3-arylquinoxalines-2-carbonitrile di-N-oxide 
 
3.5. Ketone derivatives 
 
In spite of the good results obtained from 
the 2-carbonitrile derivatives, in view of the 
toxicity data27, 37 a decision was made to 
substitute the carbonitrile group in C-2 of the 
quinoxaline ring for a carbonyl group. Taking 
into account the activity of the previously 
described compound 14,23 a new family 
consisting of more than forty QDO 
derivatives38 was synthesized in order to 
analyze its in vitro activity against the 
epimastigote form of three different straws 
and one clone of T. cruzi. Optimal anti-T. cruzi 
QDO were identified from a structural point 
of view (Figure 11). First of all, we were able 
to determine the importance of the presence 
of a good electrophilic center in C-2. The 
derivatives in which the carbonyl group in C-2 
was replaced by a methylene (CH2) group 
were completely inactive at the doses 
assayed (14 vs. 39), showing the importance 
of the derivative 14. We were also able to 
confirm the importance of N-oxides because 
the optimal activity was found in the 
dioxidized form of the quinoxaline and its 
reduction led to compounds that were 
equally inactive (42 vs. 43). Derivatives with 
CF3 in C-3 were the most active in 
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comparison with derivatives with CH3 or 
phenyl group in this position (41 vs. 40 and 
45 vs. 44). Moreover, the addition of good 
electron-withdrawing substituents in 
positions 3, 6 and 7 increased the antichagas 
activity of the compounds. 
The leader compound was derivative 45, 
with anti-Tulahuen 2 activity nearly 20 times 
more active than the reference drug Nfx., 
with the best selectivity index data of the 
series (macrophage/T. cruzi) and not 
mutagenic in the Ames test.39 This compound 
contained all the structural requirements 
observed for other derivatives: a good 
electrophilic center in position C-2 and three 
excellent electron-withdrawing moieties in C-
3, C-6 and C-7 positions. 
 
Figure 11. Structural anti-T. cruzi activity for the studied quinoxalines. The IC50 refer to 
Tulahuen 2 strain 
 
3.6. Ester derivatives 
 
Continuing with the optimization based on 
the structure-activity relationships schemes 
planned by our working group, thirty 
quinoxaline 1,4-di-N-oxide derivatives were 
prepared. The synthesized derivatives were 
modified at C-2 of the quinoxaline ring, 
possessing a methyl or ethyl ester group 
instead of the ketone moiety.38,40 
The new derivatives showed excellent in 
vitro biological activity against Tulahuen 2 
strain of T. cruzi. Sixteen out of the eighteen 
compounds with CF3 in C-3 were more potent 
than the reference drug Nfx. Compound 53 
was identified as the most active, showing an 
IC50 value of 0.4 µM, 18 times more active 
than Nfx (7.7 µM). (Figure 12).In general, the 
ester derivatives improve the biological 
activity of the corresponding ketone in every 
case with the exception of substituents CF3 at 
C-3 and F at C-6 and C-7. With regard to the 
C-2 substituent, the influence of a methyl or 
ethyl group in determining the biological 
activity is not clear. Compound 53, which was 
substituted with trifluoromethyl in C-3 and 
fluoro groups at the C-6 and C-7 of the 
quinoxaline ring, was the most active and 
selective in the cytotoxicity assay (Figure 12). 
Once again, it can be confirmed that the 
most decisive structural characteristic, in 
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terms of in vitro biological activity, is the 
presence of substituents with an electron 
withdrawing character in positions 3, 6 and 7 
of the quinoxaline ring, especially fluorine 
atoms. 
 
Figure 12. Structural anti-T. cruzi activity for the studied quinoxalines. The IC50 and PGI% refer 
to Tulahuen 2 strain 
 
4. Complementary assays 
 
In previous work, the presence of the N-
oxide moiety significantly potentiated the 
activity against T. cruzi, which may indicate 
the importance of a bioreduction or 
metabolization process of these groups by 
specific enzymes within the activity of related 
with these types of derivatives.8,9,38 However, 
the mechanism of action through which 
these derivatives carry out their activity is still 
under investigation. We present some 
studies performed in an attempt to go insight 
into the mechanism of action of QDO 
derivatives. 
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4.1. Effect on mitochondrial 
dehydrogenase activity 
 
As mentioned in the introduction of this 
paper, some QDO compounds are species 
that suffer a bioreductive process under 
hypoxic conditions, producing hydroxyl 
radical and quinoxaline. This led us to believe 
that our quinoxalines could produce parasitic 
damage through the production of radical 
species affecting the redox metabolism. It has 
been demonstrated that mitochondrial 
dehydrogenases could be involved in the 
mechanism of action of N-oxide containing 
heterocycles, such as furoxans and 
benzofuroxans.41,42 In order to better 
understand the anti-T. cruzi mechanism of 
action of our compounds, we studied the 
effect of some selected QDO derivatives: 
compound 13 (Figure 5) and compounds 41, 
42 and 45 (Figure 11), on the mitochondrial 
dehydrogenase activity in comparison with 
the reference drug, Nfx.40 The results show 
that Nfx. does not affect the mitochondrial 
dehydrogenase activity, while the 
quinoxaline derivatives (compound 13, 41, 42 
and 45) produce a decrease in a time-
dependent manner (Figure 13). With this 
assay, we were able to demonstrate that 
mitochondria are affected when these 
derivatives are used. 
 
 
Figure 13. Variation of the percentage of mitochondrial dehydrogenase activity (Pmdh), 
produced by the compounds 13, 41, 42 and 45 with respect to time, compared to the 
untreated control of T. cruzi epimastigote, Y strain, using the colorimetric MTT assay with a 
described procedure43 
 
4.2. Cyclic voltammetry studies 
 
In previous studies, an inhibition of 
mitochondrial dehydrogenases was 
demonstrated and it was also observed that 
benzofuroxan derivatives containing N-oxide 
cause a mitochondrial membrane 
depolarization in T. cruzi.38, 41, 42 In order to 
shed some light on this subject, a study was 
conducted which involved the measuring of 
the reduction potentials of the N-oxide 
groups in different synthesized derivatives 
and selected analogs. The experimental goal 
of these studies was to determine the 
reduction potentials for two series of QDO: 
ketone44 and ester40 derivatives, in order to 
obtain evidence of the relationship between 
Moreno-Viguri, E.; Pérez-Silanes, S. 
 
 
Rev. Virtual Quim. |Vol 5|  |No. 6|  |1101-1119| 1113 
 
their electrochemical behaviour, their 
structure, and their anti-T. cruzi activity. The 
electrochemical properties of these 
compounds were studied using cyclic 
voltammetry and first derivative cyclic 
voltammetry in DMF with (Bu4N)ClO4 as 
supporting electrolyte. All reductions were 
diffusion-controlled, as indicated by fairly 
constant current functions at varying scan 
rates for each derivative.45,46 
With respect to the mechanism, the 
heterocyles di-N-oxide as anti-Chagasic 
agents that possess the di-iminio structure 
are expected to suffer a reduction by means 
of an electron in order to form a radical anion 
(Figure 14). In a first phase, the QDO could be 
activated through a process of bioreduction 
in order to form a reactive anion radical, 
which could later lead to the superoxide ion 
or other toxic reactive oxygen species, or to 
direct interactions with macromolecules in a 
subsequent phase. If this mechanism occurs 
for these compounds, the activation process 
by bioreduction would generally be expected 
to be simpler for those compounds that can 
be reduced more easily or in other words, for 
those compounds that show less negative 
reduction potentials. 
 
 
 
Figure 14. One electron reduction of QDO to form a radical anion 
 
In the current study, several 
voltammmetric waves were observed during 
cyclic voltammetry of the QDO derivatives 
between -0.4 and 2.3 V. The first reduction 
process observed in the voltamogrames may 
be attributed to reduction of the nitrone 
functionality, forming a radical anion.  
In this way, it was found that the structure 
influences both the reduction potentials and 
the activities of the studied compounds; 
therefore, a relationship between reduction 
potential and activity for the described 
quinoxaline derivatives is possible (Table 1). 
The presence of electron-withdrawing 
substituents in C-3, C-6 and C-7 of the 
quinoxaline ring resulted in a positive shift in 
reduction potential. Compounds with less 
negative values of reduction potential 
generally showed greater efficacy against the 
parasite. These results suggested that a 
bioreduction process of the N-oxides might 
be taking place in the mechanism of action of 
these types of derivatives. 
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Table1. Structure, cyclic voltammmetric data and anti-Chagas activity of the QDO. aE1/2= 
Half-wave potentials for ferrocene. bPercentage of growth inhibition of Tulahuen 2 strain, dose 
cIC50= concentration that inhibits 50% of epimastigote form of T. cruzi growth 
 
R2 R3 R6/R7 
Cyclic 
voltammetry 
Anti-Chagas activity 
E1/2[V]
a PGI [%]b IC50 [M]
c 
43 -Ph -CF3 F/F -1.188 100 0.7 
44 -Ph -CF3 H/H -1.308 100 0.9 
47 -CH3 -CF3 F/F -1.179 100 0.39 
49 -OCH2CH3 -CH3 CH3/CH3 -1.677 1 - 
51 -OCH2CH3 -CF3 H/OCH3 -1.357 100 4.8 
53 -OCH2CH3 -CF3 H/H -1.281 100 4.0 
54 -OCH3 -CF3 H/H -1.313 100 2.6 
55 -OCH2CH3 -CF3 F/F -1.161 100 0.4 
56 -OCH3 -CF3 F/F -1.160 100 1.5 
57 -CH2CH3 -CF3 Cl/Cl -1.093 100 0.78 
58 -OCH3 -CH3 Cl/Cl -1.366 66 - 
59 -OCH2CH3 -CH3 Cl/Cl -1.370 32 - 
60 -OCH3 -CF3 Cl/Cl -1.076 100 10.8 
61 -OCH2CH3 -CF3 Cl/Cl -1.081 100 2.9 
 
 
The information obtained will be useful 
for the design of new derivatives in the 
future with greater biological activities 
against T. cruzi and better toxicity profiles. 
 
4.3. Metabolites 
 
In an attempt of elucidating the 
mechanism of action of QDO and taking into 
account the results previously obtained in the 
mitochondrial dehydrogenase activity assay, 
some derivatives were selected for studying 
the modification of excreted metabolites by 
1H-NMR. Studying the changes in the 
biochemical pathway is a very useful tool in 
the elucidation of mechanism of action; 
therefore, cell-free medium of quinoxaline-
treated parasite where compared to the 
untreated T. cruzi-free medium.38,41,47 
The changes in the most relevant 
modified metabolites were studied (Figure 
15). It can be observed that the end-
metabolite concentration is lower when 
parasites are treated with compound 13 in 
comparison with 41-treated parasites. This 
fact could be explained considering that 
compound 13 is a better mitochondrial 
dehydrogenase inhibitor as it can be 
observed in Figure 15. 
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Figure 15. Percentage of the end-metabolite excreted to the medium by T. cruzi (Y strain), in 
different treatments 
 
4.4. In vivo assays 
 
Considering the promising results of some 
of the studied quinoxalines, derivatives 41 
and 45 were selected for in vivo assays.38 
These derivatives had previously showed 
good selectivity, were active against 
trypomastigote form of T. cruzi and were not 
mutagenic in the Ames test. 
The selected compounds were evaluated 
in murine models of acute Chagas disease. 
Three different experiments were carried out 
and weekly parasitemia, animal survival 
percentages and anti-T. cruzi antibody levels 
after the infection were studied to evaluate 
the in vivo activity. The studies revealed 
greater survival rates at the end of the 
experiments when the animals were treated 
with derivative 41. 
In one of the experiments animals were 
infected with Y-trypomastigotes and 
compounds 41 and 45 were administered at 
10 or 30 and 10 (mg/kg bw) day, respectively. 
The study revealed that both derivatives 
avoided the second parasitemia maximum 
which is shown if treated with Bzn. Animals 
treated with derivative 41 presented lower 
numbers of trypomastigotes in a non-dose 
dependence, while animals treated with 
derivative 45 did not improve the parasitemia 
profile (Figure 16a).The observed antibody 
levels for 41 and Bzn-treated animals were 
lower than the values for the control group 
(PBS), although no significant differences 
between 41 and 45-treated were found at 
day 90 after infection (Figure 16b). 
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Figure 16. Y-trypomastigotes infected animals. a) Parasitemia in mice. b) Anti-T. cruzi antibody 
levels 
 
Two experiments were carried out in 
animals infected with CL Brener 
trypomastigotes. 45-treated animals showed 
a better parasitemia profile in agreement 
with the antibodies values that were lower 
than when treated with derivative 41 (Figure 
17). 
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(a) (b) 
  
Figure 17. CL Brener trypomastigotes infected animals. a) Parasitemia in mice. b) Anti-T. cruzi 
antibody levels 
 
5. Conclusions 
 
During the last decade QDO have shown 
activity against T. cruzi. A continuous 
evaluation of more than 200 quinoxaline 
derivatives as anti-trypanosomatid agents 
has allowed us to establish some structural 
requirements highlighting the relevance of N-
oxide moiety and electro withdrawing 
substituents on the quinoxaline ring. 
Moreover, it has been established that 
mitochondria are affected when using QDO 
derivatives. The voltammetric results provide 
some pieces of information that may be 
important for understanding the mechanism 
of anti-T-cruzi activity for these compounds 
and suggest a possible relationship between 
ease of reduction and activity. In addition, 
due to the in vitro activity against T. cruzi and 
the lack of mutagenesis properties, 
derivatives 41 and 45 were moved on to 
preliminary in vivo assays showing very 
interesting profiles. These promising results 
make them valid as new leads for 
synthesizing new derivatives which could 
improve the anti T. cruzi activity. Additional 
studies are currently being carried out with 
ester derivatives. 
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